Recruiting
Phase 2

Observational Study

Sponsor:

TruDiagnostic

Code:

NCT05535608

Conditions

Aging

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Accepted

Interventions

SRW Cel System

Study Details

Brief summary:

SRW Laboratories has formulated the Cel System protocol, a group of three formulas designed to interact with each of the 9 Hallmarks of Aging and combined this with an App that supports positive lifestyle changes, with a view that, if we can positively impact each Hallmark, we can support healthy aging.

Conditions

Aging

Study ID

NCT05535608

Start date

Aug 15, 2022

Status verified date

Sep, 2022

Completion date

Dec 31, 2023

Anticipated

Primary completion date

Dec 31, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Men and women of any ethnicity
  • 55 years and older
  • Female subjects must be post-menopausal
  • Participant must be able to comply with treatment plan and laboratory tests
  • Participant must be able to read, write, and speak English fluently
  • Participant must have a smartphone and be able to download and use the App
  • Participant must have an established primary care provider
  • Participant must be willing and able to consume study supplements throughout the duration of study period

Exclusion Criteria:

  • History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  • Known immune system issues or immunodeficiency disease
  • History of viral illness which could be reactivated by immune downregulation
  • Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
  • Diagnosis of a transient ischemic attack in the 6 months prior to screening
  • Participants infected with hepatitis C or HIV
  • Presence of active infection in previous 4 weeks
  • Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the Clinical Investigator would render a participant unsuitable to participate in the study
  • Unable or unwilling to provide required blood sample for testing
  • Current or previous use of known prescription immunomodulating products (e.g. glucocorticoids, TNF-alpha inhibitors) in the month prior to the start of the trial.
  • A known history of blood dyscrasias including coagulopathy
  • Any person deemed by the Investigator as having a low likelihood of complying with study protocol (e.g. evidence of history of non-compliance, history of poor follow-up, multiple or complex scheduling conflicts).
  • Planned surgical procedure during study period
  • Participants who are actively engaged in a weight loss program or have started any new medications during the duration of the trial that can potentially interfere with the study, as deemed appropriate by Principal Investigator.

Study Design

Enrollment

50 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: SRW Cel system

Cel1, Cel2, Cel3

Patients will take all three supplements once daily. Patients will take 2 capsules of each supplement in the morning with food.

Interventions

SRW Cel System

Dietary supplement

Primary outcome measure

  • Biological age [ Time Frame: Change in epigenetic age from baseline to 12 months ]

Central Contacts and Locations

Locations

Regenerative Wellness Center

Recruiting

Salt Lake City, Utah, United States, 84117

Contacts

Lisa Sanders

801-797-5901info@regwellness.com

Daniel Garcia

8017975901info@regwellness.com

Principal Investigator:

Steve Warren, MD

More Information

Sponsor

TruDiagnostic

Last update posted

Sep 10, 2022

Last verified

Sep, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by TruDiagnostic on 2022-09-10.